Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model
- 1 January 2022
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 322 (1) , F27-F41
Abstract
Autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in the polycystin 1 (PKD1) or polycystin 2 genes, presents with progressive development of kidney cysts and eventual end-stage kidney disease with limited treatment options. Previous work has shown that metformin reduces cyst growth in rapid ADPKD mouse models via inhibition of cystic fibrosis transmembrane conductance regulator-mediated fluid secretion, mammalian target of rapamycin, and cAMP pathways. The present study importantly tested the effectiveness of metformin as a therapy for ADPKD in a more clinically relevant Pkd1RC/RC mouse model, homozygous for the R3277C knockin point mutation in the Pkd1 gene. This mutation causes ADPKD in humans. Pkd1RC/RC male and female mice, which have a slow progression to end-stage kidney disease, received metformin (300 mg/kg/day in drinking water vs. water alone) from 3 to 9 or 12 mo of age. As previously reported, Pkd1RC/RC females had a more severe disease phenotype as compared with males. Metformin treatment reduced the ratio of total kidney weight-to-body weight relative to age-matched and sex-matched untreated controls at both 9 and 12 mo and reduced the cystic index in females at 9 mo. Metformin also increased glomerular filtration rate, lowered systolic blood pressure, improved anemia, and lowered blood urea nitrogen levels relative to controls in both sexes. Moreover, metformin reduced gene expression of key inflammatory markers and both gene and protein expression of kidney injury marker-1 and cyclin-dependent kinase-1 versus untreated controls. Altogether, these findings suggest several beneficial effects of metformin in this highly relevant slowly progressive ADPKD mouse model, which may help inform new ADPKD therapies in patients. NEW & NOTEWORTHY Metformin treatment improved ADPKD disease severity in a relevant, slowly progressive ADPKD mouse model that recapitulates a PKD-associated PKD1 mutation. Relative to controls, metformin reduced kidney weight/body weight, cystic index and BUN levels, while improving GFR, blood pressure and anemia. Metformin also reduced key inflammatory and injury markers, along with cell proliferation markers. These findings suggest several beneficial effects of metformin in this ADPKD mouse model, which may help inform new ADPKD therapies in patients.Keywords
Funding Information
- University Kidney Research Organization
- Keck School of Medicine, University of Southern California
- U.S. Department of War (W81XWH-15-1-0420)
This publication has 78 references indexed in Scilit:
- AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial functionJournal of Clinical Investigation, 2013
- Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severityJournal of Clinical Investigation, 2012
- Evaluation of urine biomarkers of kidney injury in polycystic kidney diseaseKidney International, 2012
- Preactivation of AMPK by metformin may ameliorate the epithelial cell damage caused by renal ischemiaAmerican Journal of Physiology-Renal Physiology, 2011
- Activating AMP-activated protein kinase (AMPK) slows renal cystogenesisProceedings of the National Academy of Sciences, 2011
- Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK ActivationCell Metabolism, 2010
- Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cellsClinical and Experimental Immunology, 2009
- A tumor necrosis factor-α–mediated pathway promoting autosomal dominant polycystic kidney diseaseNature Medicine, 2008
- Cdk1 is sufficient to drive the mammalian cell cycleNature, 2007
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001